ZyVersa Therapeutics Inc. (OTCQB: ZVSA) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ZYVERSA THERAPEUTICS INC.

ZyVersa Therapeutics Inc. (OTCQB: ZVSA)
Listen to this Section


$0.20
+0.0250 ( +14.29% ) 13.8K

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

Clinical Trial Pipeline Stages


Drug Name Stage
Cholesterol Efflux Mediatorâ„¢ VAR 200DetailsDiabetic Kidney Disease Phase 2a

Market Data


Open $0.20
Previous Close $0.18
Volume 13.8K
Market Cap $1.62M
Day Range $0.17 - $0.20
52 Week Range $0.11 - $1.67
Shares Outstanding 8.10M
Change % +14.29%
Net Change ▲ 0.0250
Insider Ownership N/A
Exchange OTCQB
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year
CountryUnited States
UnderwriterA.G.P., Brookline Capital Markets, more

Insider Ownership Transactions

Total Amount Purchased: -3,442.00

Date Type Amount Purchased Purchaser
2024-07-18 Sale -132.00 Freitag Gregory Gene
2024-07-18 Sale -572.00 Cashmere Karen A.
2024-07-18 Sale -132.00 Park Min-Chul
2024-07-18 Sale -132.00 Finizio Robert G
2024-07-18 Sale -132.00 SAPIRSTEIN JAMES
2024-07-18 Sale -1627.00 Glover Stephen C.
2024-07-18 Sale -715.00 Wolfe Peter

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Jul 15, 2025
4 Insider transactions 1 Jul 15, 2025
4 Insider transactions 1 Jul 15, 2025
8-k 8K-related 16 Jul 09, 2025
8-k 8K-related 15 Jun 25, 2025
8-k 8K-related 13 Jun 12, 2025

Latest News


× Before browsing our site, please accept our cookies policy